keyword
https://read.qxmd.com/read/38540977/a-multidisciplinary-approach-to-the-management-of-eales-disease-a-case-report-and-review-of-the-literature
#1
Maria Filoftea Mercuț, Oana Maria Ică, Cornelia Andreea Tănasie, Răzvan Mercuț, Carmen Luminița Mocanu, Andreea Mihaela Nicolcescu, Ciprian Danielescu
Eales disease manifests as an obliterative periphlebitis affecting the retina; it originates from the periphery and progresses posteriorly. It is characterized by retinal vessel wall inflammation, ischemia, and retinal neovascularization. In this report, we present the case of a 34-year-old male who attended our clinic with a sudden blurring of vision in his right eye. A diagnosis of bilateral retinal vasculitis with vitreal hemorrhage was ascertained in his RE. A dilated ocular fundus examination revealed perivenous sheathing of the peripheral vessels in both eyes...
February 22, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38539054/value-of-autotaxin-for-hepatocellular-carcinoma-risk-assessment-in-chronic-hepatitis%C3%A2-b-patients-treated-with-nucleos-t-ide-analogs
#2
JOURNAL ARTICLE
Yuichi Hiyama, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
AIM: Autotaxin (ATX) is a newly identified liver fibrosis biomarker; however, its clinical usefulness remains unclear. Therefore, we analyzed the changes in patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogs (NAs) to evaluate its usefulness. We also investigated the predictors of hepatocellular carcinoma development, including ATX, in patients with chronic hepatitis B based on their clinical characteristics. METHODS: This retrospective study included 179 patients with hepatitis B virus infection treated with NAs for >2 years...
March 27, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://read.qxmd.com/read/38527527/alt-to-qhbsag-ratio-predicts-long-term-hbsag-seroclearance-after-entecavir-cessation-in-chinese-patients-with-chronic-hepatitis-b
#3
JOURNAL ARTICLE
Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen
BACKGROUND: Factors predicting HBsAg seroclearance after treatment cessation, irrespective of nucleos(t)ide analogue (NA) resumption, have important clinical implications. We evaluated predictors of long-term HBsAg seroclearance after entecavir cessation. METHODS: This study followed up Chinese chronic hepatitis B patients from two previous studies of entecavir cessation. All patients were non-cirrhotic, HBeAg-negative, with undetectable HBV DNA (<20 IU/ml) at end-of-treatment (EOT)...
March 23, 2024: Journal of Hepatology
https://read.qxmd.com/read/38517681/switching-from-combination-therapy-with-entecavir-hydrate-plus-tenofovir-alafenamide-fumarate-to-tenofovir-alafenamide-fumarate-monotherapy-in-patients-with-chronic-hepatitis%C3%A2-b-based-on-nucleotide-sequences-of-hepatitis%C3%A2-b-virus-pregenome-rna
#4
JOURNAL ARTICLE
Shunsuke Yamada, Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Shohei Tsuji, Hayato Uemura, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Suguru Mizuno, Satoshi Mochida
AIM: Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir alafenamide fumarate (TAF) due to the emergence of a drug-resistance mutation. However, in patients lacking drug-resistance mutation against TAF, sufficient antiviral effects may be achievable with TAF monotherapy. We assessed the drug-resistance profile through nucleotide sequences of HBV pregenome RNA, and subsequently changed to TAF monotherapy from ETV plus TAF...
March 22, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://read.qxmd.com/read/38480009/mortality-in-patients-with-chronic-hepatitis-b-treated-with-tenofovir-or-entecavir-a-multinational-study
#5
JOURNAL ARTICLE
Tyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih-Wen Wang, Man-Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Korenobu Hayama, Masatoshi Ishigami, Yong Kyun Cho, Eiichi Ogawa, Hyoung Su Kim, Jae-Jun Shim, Haruki Uojima, Soung Won Jeong, Sang Bong Ahn, Koichi Takaguchi, Tomonori Senoh, Maria Buti, Elena Vargas-Accarino I, Hiroshi Abe, Hirokazu Takahashi, Kaori Inoue, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Wan-Long Chuang, Mindie H Nguyen, Ming-Lung Yu
BACKGROUND AND AIM: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear. METHODS: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups...
March 13, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38472967/long-term-hbsag-titer-kinetics-with-entecavir-tenofovir-implications-for-predicting-functional-cure-and-low-levels
#6
JOURNAL ARTICLE
Soon Kyu Lee, Soon Woo Nam, Jeong Won Jang, Jung Hyun Kwon
The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled patients newly treated with entecavir or tenofovir, we analyzed 852 patients who underwent serial HBsAg level checks every 6-12 months. The primary outcomes included long-term kinetics in HBsAg levels and the rate of functional cure and achieving low HBsAg levels...
February 25, 2024: Diagnostics
https://read.qxmd.com/read/38457543/coxsackie-b-virus-induced-myocarditis-in-a-patient-with-a-history-of-lymphoma-a-case-report-and-review-of-literature
#7
JOURNAL ARTICLE
Qian Zhang, Jia Yuan, Wei Zhao, Weiwei Ouyang, Bowen Chen, Yehong Li, Junling Tao, Xianjun Chen, Guangsu Li, Zhendong Guo, Ying Liu
INTRODUCTION: In rare occasions, coxsackievirus infections can cause serious illness, such as encephalitis and myocarditis. The immunotherapies of cancer could increase the risk of myocarditis, especially when applying immune checkpoint inhibitors. Herein, we report a rare case of Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma. CASE PRESENTATION: A 32-year-old woman was admitted to the hospital with recurrent fever for more than 20 days, and she had a history of lymphoma...
March 8, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38455623/polymyositis-concomitant-with-hepatitis-b-virus-infection-treatment-challenges
#8
JOURNAL ARTICLE
Andi R Ginting, Vincent Tandiono
Polymyositis is a chronic autoimmune disease that presents with symmetrical progressive proximal muscle weakness. The cause of this disease due to abnormal activation of macrophages that might be associated with systemic diseases such as other autoimmune diseases, malignancy or viral infections including hepatitis B virus. The aim of this case report was to highlight treatment challenges in a patient with polymyositis concomitant with hepatitis B. A 28-years-old man with history of completed hepatitis B treatment with negative viral load presented with symmetrical progressive weakness on both inferior proximal extremities...
December 2023: Narra J
https://read.qxmd.com/read/38450105/hbsag-kinetics-after-7-years-of-therapy-with-tenofovir-disoproxil-fumarate-in-a-cohort-of-na%C3%A3-ve-patients-affected-by-chronic-hepatitis-b-with-different-genotypes
#9
JOURNAL ARTICLE
Lucio Boglione, Tommaso Lupia, Giacomo Stroffolini, Valentina Dodaro, Giovanni Di Perri
The role of different genotypes in nucleos(t)ide analogs (NAs) treatment is still debated. Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serological response. This descriptive study aims to recognize the hepatitis B "s" antigen (HBsAg) decline during tenofovir disoproxil fumarate (TDF) treatment in a cohort of patient affected by chronic hepatitis B (CHB). We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 years...
March 2024: Infect Med (Beijing)
https://read.qxmd.com/read/38438842/impact-of-preoperative-antiviral-therapy-on-the-prognosis-of-hepatitis-b-virus-related-hepatocellular-carcinoma
#10
JOURNAL ARTICLE
Yuxin Liang, Deyuan Zhong, Zilong Zhang, Yuhao Su, Su Yan, Chunyou Lai, Yutong Yao, Ying Shi, Xiaolun Huang, Jin Shang
BACKGROUND: For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of antiviral therapy for hepatocellular carcinoma (HCC) remains to be further explored. METHODS: 196 HBV-related HCC patients who received radical hepatectomy and nucleos(t)ide analogues (NAs) therapy at Sichuan Provincial People's Hospital were enrolled in this study...
March 4, 2024: BMC Cancer
https://read.qxmd.com/read/38436992/chronic-hepatitis-b-baseline-viral-load-and-on-treatment-liver-cancer-risk-a-multinational-cohort-study-of-hbeag-positive-patients
#11
JOURNAL ARTICLE
Won-Mook Choi, Terry Cheuk-Fung Yip, W Ray Kim, Leland J Yee, Craig Brooks-Rooney, Tristan Curteis, Laura J Clark, Zarena Jafry, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Wook Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Jung Woo Shin, Yao-Hsu Yang, Grace Lai-Hung Wong, Young-Suk Lim
BACKGROUND AND RATIONALE: A single-nation study reported that pre-treatment hepatitis B virus (HBV) viral load is associated with on-treatment risk of hepatocellular carcinoma (HCC) in hepatitis B e antigen (HBeAg)-positive, non-cirrhotic, chronic hepatitis B (CHB) patients initiating antiviral treatment. We aimed to validate the association between baseline HBV viral load and on-treatment HCC risk in a larger, multinational cohort. METHODS: Using a multinational cohort from Korea, Hong Kong, and Taiwan involving 7,545 HBeAg-positive, non-cirrhotic, adult CHB patients who started entecavir or tenofovir treatment with baseline HBV viral load ≥5...
January 24, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38423922/tenofovir-versus-entecavir-on-recurrence-and-mortality-of-hepatitis-b-virus-related-hepatocellular-carcinoma-after-curative-therapy
#12
JOURNAL ARTICLE
Kai-Chun Chang, Tung-Hung Su, Sih-Han Liao, Tai-Chung Tseng, Shang-Chin Huang, Shih-Jer Hsu, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
BACKGROUND: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) reduce the risk of hepatocellular carcinoma (HCC) in patients of hepatitis B. This study compared the difference between ETV and TDF on risk of HCC recurrence and mortality in patients with HBV-related HCC after curative intent treatment. METHODS: Patients with HBV-related HCC who received HCC treatment (surgery or radiofrequency ablation [RFA]) and underwent long-term ETV or TDF therapy were retrospectively included...
February 28, 2024: Journal of the Formosan Medical Association
https://read.qxmd.com/read/38418664/-diagnosis-and-treatment-of-viral-hepatitis%C3%A2-b-and%C3%A2-d-in-2024
#13
REVIEW
Roni Souleiman, Markus Cornberg
Despite the availability of vaccines, hepatitis B remains a significant cause of fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. The increase in reported hepatitis B cases in Germany is attributed to factors such as immigration and the hepatitis B surface antigen (HBsAg) screening introduced in 2020 as part of health check-ups. The indication for treatment depends on various factors, including the level of hepatitis B virus (HBV) DNA and inflammatory activity...
February 28, 2024: Inn Med (Heidelb)
https://read.qxmd.com/read/38401714/an-in-vivo-duck-hepatitis-b-virus-model-recapitulates-key-aspects-of-nucleic-acid-polymer-treatment-outcomes-in-chronic-hepatitis-b-patients
#14
JOURNAL ARTICLE
Yannick Debing, Hannah Vanrusselt, Lars Degrauwe, Daniel Apolônio Silva de Oliveira, Christopher Kinyanjui Kariuki, Ebanja Joseph Ebwanga, Shahbaz Bashir, Wouter Merckx, Santhosh Kumar Thatikonda, Vivek Rajwanshi, Vikrant Gohil, Jin Hong, Dieudonné Buh Kum, Abel Acosta Sanchez, Sushmita Chanda, Lawrence M Blatt, Andreas Jekle, Julian A Symons, David B Smith, Pierre Raboisson, Tse-I Lin, Leonid Beigelman, Jan Paeshuyse
Nucleic acid polymers (NAPs) are an attractive treatment modality for chronic hepatitis B (CHB), with REP2139 and REP2165 having shown efficacy in CHB patients. A subset of patients achieve functional cure, whereas the others exhibit a moderate response or are non-responders. NAP efficacy has been difficult to recapitulate in animal models, with the duck hepatitis B virus (DHBV) model showing some promise but remaining underexplored for NAP efficacy testing. Here we report on an optimized in vivo DHBV duck model and explore several characteristics of NAP treatment...
February 23, 2024: Antiviral Research
https://read.qxmd.com/read/38398204/cost-utility-analysis-of-tenofovir-alafenamide-and-entecavir-in-chronic-hepatitis-b-patients-a-markov-decision-model
#15
JOURNAL ARTICLE
Chun-Huang Lai, Hon-Yi Shi, Cheng-En Tsai, Yuan-Chieh Yang, Si-Un Frank Chiu
From the perspective of health economics, the evaluation of drug-related cost effectiveness and clinical utility is crucial. We conducted a cost-utility analysis of two first-line drugs, tenofovir alafenamide (TAF) and entecavir (ETV), in the treatment of chronic hepatitis B (CHB) patients. We performed inverse probability of treatment weighting (IPTW) to match the independent variables between the two treatment groups. The incremental cost effectiveness ratio (ICER) of the two treatment groups was simulated using a decision tree with the Markov annual-cycle model...
February 17, 2024: Cancers
https://read.qxmd.com/read/38343610/hepatocellular-carcinoma-with-gastric-metastasis-mimicking-a-4-cm-gastrointestinal-stromal-tumor-after-a-3-year-disease-free-interval
#16
Wei-Ting Chen, Shiu-Feng Kathy Huang, Ming-Ling Chang, Yun-Fan Liaw
Hepatocellular carcinoma (HCC) is an aggressive tumor that usually occurs in patients with chronic liver disease and cirrhosis. Surgical resection is an optimal treatment for HCC, but the 5-year recurrence rates are significantly high. The majority of recurrent HCCs occur through intrahepatic metastasis with local tumor progression, and less than 20% of recurrences are extrahepatic metastases. HCC with gastric metastasis is extremely rare, and it is easily misdiagnosed as primary gastric cancer with liver metastasis...
February 28, 2024: Journal of Clinical and Translational Hepatology
https://read.qxmd.com/read/38335376/splenic-marginal-zone-lymphoma-with-monoclonal-igg-a-case-report
#17
JOURNAL ARTICLE
Xupai Zhang, Shihui Ren, Nan Zhang, Xiao Wang, Lin Qiu, Haoping Sun, Hai Yi, Fangyi Fan
RATIONALE: Splenic marginal zone lymphoma (SMZL), an indolent small B-cell lymphoma, is uncommon, and part of the patients exist plasmocytic differentiation and secrete monoclonal paraproteins including IgM predominantly. SMZL with monoclonal IgG is rarer. PATIENT CONCERNS: We report a case of SMZL (49-year-old, male) with monoclonal IgG, MYD88L265P mutation and hepatitis B virus infection. DIAGNOSES: The patient was presented to our hospital with aggravating complaints of dizziness, fatigue, postprandial abdominal distension, and night sweats...
February 9, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38320787/-17-year-study-on-the-curative-effect-of-treatment-to-prevent-the-recurrence-of-hepatitis-b-in-different-risk-groups-after-liver-transplantation
#18
JOURNAL ARTICLE
D L Zhang, X He, D N Feng, M J Ren, Y H Guang, L X Li, H B Wang, Z W Liu
Objective: To observe the recurrence condition of hepatitis B in different risk groups after liver transplantation in an attempt to provide useful information on whether to discontinue hepatitis B immunoglobulin (HBIG) in the future at an early stage. Methods: The patient population was divided into high, low-risk, and special groups [especially primary hepatocellular carcinoma (HCC)] according to the guidelines for the prevention and treatment of hepatitis B recurrence after liver transplantation. The recurrence condition and risk factors in this population were observed for hepatitis B...
January 20, 2024: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://read.qxmd.com/read/38317634/cost-effectiveness-of-switching-from-tenofovir-disoproxil-fumarate-to-tenofovir-alafenamide-versus-entecavir-for-chronic-hepatitis-b-patients-in-greece
#19
JOURNAL ARTICLE
Emmanouil Sinakos, Nandita Kachru, Christos Tsoulas, Sushanth Jeyakumar, Nathaniel J Smith, Alon Yehoshua, Evangelos Cholongitas
Aim: This study assessed the clinical impact and cost-effectiveness of switching from tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) in a Greek chronic hepatitis B (CHB) population. Patients & methods: A Markov model from the perspective of a third-party payer in Greece quantified the health and economic benefits of switching from TDF to either TAF or ETV over a lifetime horizon. Results: Over a lifetime, patients who switch from TDF to TAF versus patients who switch from TDF to ETV had an overall lower incidence of compensated cirrhosis (0...
February 6, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38315445/unveiling-the-molecular-interaction-of-hepatitis-b-virus-inhibitor-entecavir-with-human-serum-albumin-through-computational-microscopic-and-spectroscopic-approaches
#20
JOURNAL ARTICLE
Mujaheed Abubakar, Saharuddin B Mohamad, Adyani Azizah Abd Halim, Saad Tayyab
Molecular docking, molecular dynamics (MD) simulation, atomic force microscopy (AFM) and multi-spectroscopic techniques were selected to unveil the molecular association between the hepatitis B virus (HBV) inhibitor, entecavir (ETR), and the major blood plasma transporter, human serum albumin (HSA). The entire docking and simulation analyses recognized ETR binding to subdomain IIA (Site I) of HSA through hydrogen bonds, hydrophobic and van der Waals forces while maintaining the complex's stability throughout the 100 ns...
February 5, 2024: Journal of Biomolecular Structure & Dynamics
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.